Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium.
J Hum Genet. 2012 Apr;57(4):277-9. doi: 10.1038/jhg.2012.1. Epub 2012 Jan 26.
Albright's hereditary osteodystrophy (AHO) is characterized by short stature, round face, calcifications, obesity, brachydactyly and intellectual disability. AHO without hormone resistance is called pseudopseudohypoparathyroidism (PPHP), a rare clinical condition difficult to diagnose with highly variable features. PPHP is caused by paternally inherited loss-of-function mutations in the GNAS. Patients with 2q37 microdeletions or HDAC4 mutations are also defined as having an AHO-like phenotype with normal stimulatory G (Gs) function. We have studied 256 patients with AHO features but no other diagnosis. Their platelet Gs activity was determined via the aggregation-inhibition test showing Gs hypo- or hyperfuncton in 24% and 15% of the patients, respectively. Before initiating with detailed (epi)genetic GNAS studies, we here wanted to excluded copy number variants (CNVs) in GNAS as cause of AHO with a novel large-scale screening technique. Multiplex amplicon quantification (MAQ) for CNVs screening was developed for the 20q13.3 region including GNAS and potential long-range imprinting control elements such as STX16. This is the first large-scale GNAS CNV study in patients with common AHO features but no CNVs were detected. In conclusion, CNVs in the GNAS region are not likely to cause an AHO-like phenotype with or without abnormal platelet Gs activity. Future studies will be undertaken to find out whether these AHO patients with abnormal Gs function are characterized by GNAS coding or methylation defects.
阿利布尔特遗传性骨营养不良症(AHO)的特征是身材矮小、圆脸、钙化、肥胖、短指畸形和智力障碍。对激素不敏感的 AHO 称为假性假性甲状旁腺功能减退症(PPHP),这是一种罕见的临床病症,难以诊断,且具有高度可变的特征。PPHP 是由父系遗传的 GNAS 功能丧失突变引起的。具有 2q37 微缺失或 HDAC4 突变的患者也被定义为具有正常刺激 G(Gs)功能的 AHO 样表型。我们研究了 256 名具有 AHO 特征但无其他诊断的患者。通过聚合抑制试验测定其血小板 Gs 活性,分别有 24%和 15%的患者 Gs 功能低下或功能亢进。在开始详细的( epi )遗传 GNAS 研究之前,我们希望用一种新的大规模筛选技术排除 GNAS 中的拷贝数变异(CNVs)作为 AHO 的原因。为包括 GNAS 在内的 20q13.3 区域开发了用于 CNV 筛选的多重扩增子定量(MAQ)技术,以及 STX16 等潜在的长距离印迹控制元件。这是首次在具有常见 AHO 特征但未检测到 CNVs 的患者中进行的大规模 GNAS CNV 研究。总之,GNAS 区域的 CNVs 不太可能导致具有或不伴有异常血小板 Gs 活性的 AHO 样表型。未来的研究将致力于发现这些具有异常 Gs 功能的 AHO 患者是否具有 GNAS 编码或甲基化缺陷的特征。